# P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

> **NCT03119012** · PHASE4 · TERMINATED · sponsor: **Samsung Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Coronary Artery Disease
- Stents
- Atherosclerosis

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Ticagrelor
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT03119012
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-19
- **Primary completion:** 2017-12-18
- **Final completion:** 2018-02-09
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** cannot use bioabsorbable scaffold
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119012, "P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03119012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*